studies

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), cemiplimab vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsEMPOWER lung1 (all population), 2021 0.68 [0.53; 0.87] EMPOWER lung1 (PDL1>50%), 2021 0.57 [0.42; 0.77] 0.63[0.52; 0.77]EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 202120%1,273moderatenot evaluable progression or deaths (PFS)detailed resultsEMPOWER lung1 (all population), 2021 0.59 [0.49; 0.72] EMPOWER lung1 (PDL1>50%), 2021 0.54 [0.43; 0.68] 0.57[0.49; 0.66]EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 202120%1,273moderatenot evaluable objective responses (ORR)detailed resultsEMPOWER lung1 (all population), 2021 2.21 [1.58; 3.10] EMPOWER lung1 (PDL1>50%), 2021 2.53 [1.32; 4.85] 2.27[1.69; 3.07]EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 202120%1,273moderatenot evaluable AE (any grade)detailed resultsEMPOWER lung1 (all population), 2021 0.18 [0.12; 0.27] 0.18[0.12; 0.27]EMPOWER lung1 (all population), 202110%697NAnot evaluable AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.19 [0.13; 0.29] 0.19[0.13; 0.29]EMPOWER lung1 (all population), 202110%697NAnot evaluable AE leading to death (grade 5)detailed resultsEMPOWER lung1 (all population), 2021 1.24 [0.46; 3.38] 1.24[0.46; 3.38]EMPOWER lung1 (all population), 202110%697NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsEMPOWER lung1 (all population), 2021 1.62 [0.82; 3.21] 1.62[0.82; 3.21]EMPOWER lung1 (all population), 202110%697NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69] 0.96[0.02; 48.69]EMPOWER lung1 (all population), 202110%697NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38] 0.48[0.02; 14.38]EMPOWER lung1 (all population), 202110%697NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70] 1.93[0.06; 57.70]EMPOWER lung1 (all population), 202110%697NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69] 0.96[0.02; 48.69]EMPOWER lung1 (all population), 202110%697NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69] 0.96[0.02; 48.69]EMPOWER lung1 (all population), 202110%697NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12] 3.87[0.17; 86.12]EMPOWER lung1 (all population), 202110%697NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70] 1.93[0.06; 57.70]EMPOWER lung1 (all population), 202110%697NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70] 1.93[0.06; 57.70]EMPOWER lung1 (all population), 202110%697NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69] 0.96[0.02; 48.69]EMPOWER lung1 (all population), 202110%697NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70] 1.93[0.06; 57.70]EMPOWER lung1 (all population), 202110%697NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70] 1.93[0.06; 57.70]EMPOWER lung1 (all population), 202110%697NAnot evaluable Rash TRAE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12] 3.87[0.17; 86.12]EMPOWER lung1 (all population), 202110%697NAnot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70] 1.93[0.06; 57.70]EMPOWER lung1 (all population), 202110%697NAnot evaluable Acute kidney injury AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34] 0.24[0.01; 5.34]EMPOWER lung1 (all population), 202110%697NAnot evaluable Alopecia AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34] 0.24[0.01; 5.34]EMPOWER lung1 (all population), 202110%697NAnot evaluable Anaemia AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.03 [0.01; 0.13] 0.03[0.01; 0.13]EMPOWER lung1 (all population), 202110%697NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38] 0.48[0.02; 14.38]EMPOWER lung1 (all population), 202110%697NAnot evaluable Asthenia AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38] 0.48[0.02; 14.38]EMPOWER lung1 (all population), 202110%697NAnot evaluable Back pain AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38] 0.48[0.02; 14.38]EMPOWER lung1 (all population), 202110%697NAnot evaluable Blood creatinine increased AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38] 0.48[0.02; 14.38]EMPOWER lung1 (all population), 202110%697NAnot evaluable Constipation AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69] 0.96[0.02; 48.69]EMPOWER lung1 (all population), 202110%697NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.96 [0.06; 15.46] 0.96[0.06; 15.46]EMPOWER lung1 (all population), 202110%697NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.16 [0.02; 1.32] 0.16[0.02; 1.32]EMPOWER lung1 (all population), 202110%697NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 1.93 [0.17; 21.41] 1.93[0.17; 21.41]EMPOWER lung1 (all population), 202110%697NAnot evaluable Fatigue AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.72 [0.16; 3.24] 0.72[0.16; 3.24]EMPOWER lung1 (all population), 202110%697NAnot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.06 [0.00; 1.03] 0.06[0.00; 1.03]EMPOWER lung1 (all population), 202110%697NAnot evaluable Hypertension AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34] 0.24[0.01; 5.34]EMPOWER lung1 (all population), 202110%697NAnot evaluable Increase AST AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 4.87 [0.57; 41.91] 4.87[0.57; 41.91]EMPOWER lung1 (all population), 202110%697NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 5.82 [0.29; 116.64] 5.82[0.29; 116.64]EMPOWER lung1 (all population), 202110%697NAnot evaluable Increased Lipase Level AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70] 1.93[0.06; 57.70]EMPOWER lung1 (all population), 202110%697NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.10 [0.01; 0.83] 0.10[0.01; 0.83]EMPOWER lung1 (all population), 202110%697NAnot evaluable myocarditis AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69] 0.96[0.02; 48.69]EMPOWER lung1 (all population), 202110%697NAnot evaluable Nausea AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.12 [0.01; 2.26] 0.12[0.01; 2.26]EMPOWER lung1 (all population), 202110%697NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.05 [0.01; 0.21] 0.05[0.01; 0.21]EMPOWER lung1 (all population), 202110%697NAnot evaluable Pancytopenia (AE grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38] 0.48[0.02; 14.38]EMPOWER lung1 (all population), 202110%697NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.96 [0.06; 15.46] 0.96[0.06; 15.46]EMPOWER lung1 (all population), 202110%697NAnot evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38] 0.48[0.02; 14.38]EMPOWER lung1 (all population), 202110%697NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.77 [0.20; 2.88] 0.77[0.20; 2.88]EMPOWER lung1 (all population), 202110%697NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70] 1.93[0.06; 57.70]EMPOWER lung1 (all population), 202110%697NAnot evaluable Rash AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 5.82 [0.29; 116.64] 5.82[0.29; 116.64]EMPOWER lung1 (all population), 202110%697NAnot evaluable Rash maculopapular AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70] 1.93[0.06; 57.70]EMPOWER lung1 (all population), 202110%697NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38] 0.48[0.02; 14.38]EMPOWER lung1 (all population), 202110%697NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.02 [0.00; 0.30] 0.02[0.00; 0.30]EMPOWER lung1 (all population), 202110%697NAnot evaluable Vomiting AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 0.12 [0.01; 2.26] 0.12[0.01; 2.26]EMPOWER lung1 (all population), 202110%697NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsEMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70] 1.93[0.06; 57.70]EMPOWER lung1 (all population), 202110%697NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:11 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220 - treatments: 1049